Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SHPG Shire (SHPG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Shire Stock (NASDAQ:SHPG) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Shire alerts:Sign Up Key Stats Today's Range$179.20▼$179.2050-Day Range$179.20▼$179.2052-Week Range$123.73▼$182.47VolumeN/AAverage Volume2.21 million shsMarket Capitalization$54.71 billionP/E Ratio11.83Dividend Yield0.19%Price TargetN/AConsensus RatingN/A Company OverviewShire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Receive SHPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter. Email Address SHPG Stock News HeadlinesShire horse rescued from cattle gridSeptember 20, 2024 | bbc.co.ukSHPG Historical DataOctober 15, 2023 | investing.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Shire Stock Hits New 52-Week High (SHPG)March 30, 2023 | thestreet.comEthiopia's Tigray conflict: Nasa shows how a war zone faded from space - BBCOctober 19, 2022 | bbc.comEthiopia civil war: Hyenas scavenge on corpses as Tigray forces retreat - BBCOctober 18, 2022 | bbc.comEthiopia civil war: Federal army seizes strategic city of Shire - Yahoo NewsOctober 18, 2022 | news.yahoo.comEthiopian war in Tigray intensifies as government soldiers capture strategic Shire - The Washington PostOctober 17, 2022 | washingtonpost.comSee More Headlines SHPG Stock Analysis - Frequently Asked Questions How were Shire's earnings last quarter? Shire plc (NASDAQ:SHPG) released its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.58 by $0.28. Shire's revenue was up 5.4% on a year-over-year basis. What other stocks do shareholders of Shire own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shire investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Meta Platforms (META), Intel (INTC), Cisco Systems (CSCO), NVIDIA (NVDA) and Biogen (BIIB). Company Calendar Last Earnings4/26/2018Today10/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SHPG CUSIPN/A CIK936402 Webwww.shire.com Phone353-1609-6000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$15.15 Trailing P/E Ratio11.83 Forward P/E Ratio11.88 P/E Growth1.54Net Income$4.27 billion Net Margins30.63% Pretax MarginN/A Return on Equity12.70% Return on Assets7.06% Debt Debt-to-Equity Ratio0.36 Current Ratio0.92 Quick Ratio0.51 Sales & Book Value Annual Sales$15.16 billion Price / Sales3.61 Cash Flow$22.71 per share Price / Cash Flow7.89 Book Value$119.43 per share Price / Book1.50Miscellaneous Outstanding Shares305,280,000Free FloatN/AMarket Cap$54.71 billion OptionableOptionable Beta0.87 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:SHPG) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shire plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shire With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.